Cerity Partners LLC Has $3.95 Million Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Cerity Partners LLC boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 8.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,642 shares of the biopharmaceutical company's stock after purchasing an additional 1,117 shares during the quarter. Cerity Partners LLC's holdings in Alnylam Pharmaceuticals were worth $3,953,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of ALNY. Bessemer Group Inc. raised its position in Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 69 shares in the last quarter. Crossmark Global Holdings Inc. bought a new position in Alnylam Pharmaceuticals in the 1st quarter valued at $275,000. GAMMA Investing LLC lifted its stake in Alnylam Pharmaceuticals by 14.3% in the first quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company's stock worth $166,000 after purchasing an additional 77 shares during the last quarter. Brighton Jones LLC bought a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $243,000. Finally, Silvercrest Asset Management Group LLC purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $1,151,000. Institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Trading Down 0.0%

NASDAQ ALNY traded down $0.01 during mid-day trading on Monday, reaching $320.52. 744,525 shares of the stock were exchanged, compared to its average volume of 851,954. The stock has a market cap of $41.79 billion, a P/E ratio of -153.36 and a beta of 0.23. The stock has a 50 day simple moving average of $306.46 and a 200-day simple moving average of $272.05. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $333.70. The company has a debt-to-equity ratio of 8.88, a current ratio of 3.04 and a quick ratio of 2.98.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to analysts' expectations of $584.32 million. Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The company's revenue for the quarter was up 20.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.16) earnings per share. On average, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Yvonne Greenstreet sold 31,640 shares of the stock in a transaction that occurred on Friday, May 30th. The shares were sold at an average price of $304.39, for a total value of $9,630,899.60. Following the completion of the transaction, the chief executive officer directly owned 48,948 shares of the company's stock, valued at $14,899,281.72. This trade represents a 39.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.20% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ALNY. HC Wainwright reiterated a "buy" rating and set a $500.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. Wells Fargo & Company increased their price target on Alnylam Pharmaceuticals from $287.00 to $333.00 and gave the company an "equal weight" rating in a report on Monday, June 30th. Scotiabank upped their target price on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a "sector outperform" rating in a report on Monday, March 31st. Bank of America increased their price target on shares of Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the company a "buy" rating in a research report on Friday, July 11th. Finally, Morgan Stanley cut their price target on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating for the company in a report on Friday, April 11th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty-three have assigned a buy rating to the company. According to data from MarketBeat, Alnylam Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $347.75.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.